Cancer Biomarker Market Size to be Worth USD 55.57 billion by 2032

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Cancer Biomarker Market Size Analysis

Global Cancer Biomarker Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Genetic Biomarker
    1. By Value
  3. Protein Biomarker
    1. By Value
  4. Other Cancer Biomarkers
    1. By Value
2. By Cancer
  1. Introduction
    1. Cancer By Value
  2. Lung Cancer
    1. By Value
  3. Prostate Cancer
    1. By Value
  4. Melanoma
    1. By Value
  5. Thyroid CancerKidney Cancer
    1. By Value
  6. Bladder Cancer
    1. By Value
  7. Leukemia
    1. By Value
  8. Non-Hodgkin's lymphoma
    1. By Value
  9. Colorectal Cancer
    1. By Value
  10. Breast Cancer
    1. By Value
  11. Other Cancers
    1. By Value
3. By Profiling Technology
  1. Introduction
    1. Profiling Technology By Value
  2. Genomics
    1. By Value
  3. Other Omics Technology
    1. By Value
  4. Ultrasound
    1. By Value
  5. MRI
    1. By Value
  6. Mammography
    1. By Value
  7. Cytogenetics
    1. By Value
  8. Bioinformatics
    1. By Value
  9. In Situ Hybridization
    1. By Value
  10. Immunoassays
    1. By Value
  11. PET
    1. By Value
  12. CT
    1. By Value
  13. Imaging Technologies
    1. By Value
  14. Proteomics
    1. By Value
  15. Omics Technologies
    1. By Value
  16. Other Cytogenetics
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Research
    1. By Value
  3. Risk Assessment
    1. By Value
  4. Prognostics
    1. By Value
  5. Diagnostics
    1. By Value
  6. Other Applications
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Genetic Biomarker
    1. By Value
  3. Protein Biomarker
    1. By Value
  4. Other Cancer Biomarkers
    1. By Value
2. By Cancer
  1. Introduction
    1. Cancer By Value
  2. Lung Cancer
    1. By Value
  3. Prostate Cancer
    1. By Value
  4. Melanoma
    1. By Value
  5. Thyroid CancerKidney Cancer
    1. By Value
  6. Bladder Cancer
    1. By Value
  7. Leukemia
    1. By Value
  8. Non-Hodgkin's lymphoma
    1. By Value
  9. Colorectal Cancer
    1. By Value
  10. Breast Cancer
    1. By Value
  11. Other Cancers
    1. By Value
3. By Profiling Technology
  1. Introduction
    1. Profiling Technology By Value
  2. Genomics
    1. By Value
  3. Other Omics Technology
    1. By Value
  4. Ultrasound
    1. By Value
  5. MRI
    1. By Value
  6. Mammography
    1. By Value
  7. Cytogenetics
    1. By Value
  8. Bioinformatics
    1. By Value
  9. In Situ Hybridization
    1. By Value
  10. Immunoassays
    1. By Value
  11. PET
    1. By Value
  12. CT
    1. By Value
  13. Imaging Technologies
    1. By Value
  14. Proteomics
    1. By Value
  15. Omics Technologies
    1. By Value
  16. Other Cytogenetics
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Research
    1. By Value
  3. Risk Assessment
    1. By Value
  4. Prognostics
    1. By Value
  5. Diagnostics
    1. By Value
  6. Other Applications
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Genetic Biomarker
    1. By Value
  3. Protein Biomarker
    1. By Value
  4. Other Cancer Biomarkers
    1. By Value
2. By Cancer
  1. Introduction
    1. Cancer By Value
  2. Lung Cancer
    1. By Value
  3. Prostate Cancer
    1. By Value
  4. Melanoma
    1. By Value
  5. Thyroid CancerKidney Cancer
    1. By Value
  6. Bladder Cancer
    1. By Value
  7. Leukemia
    1. By Value
  8. Non-Hodgkin's lymphoma
    1. By Value
  9. Colorectal Cancer
    1. By Value
  10. Breast Cancer
    1. By Value
  11. Other Cancers
    1. By Value
3. By Profiling Technology
  1. Introduction
    1. Profiling Technology By Value
  2. Genomics
    1. By Value
  3. Other Omics Technology
    1. By Value
  4. Ultrasound
    1. By Value
  5. MRI
    1. By Value
  6. Mammography
    1. By Value
  7. Cytogenetics
    1. By Value
  8. Bioinformatics
    1. By Value
  9. In Situ Hybridization
    1. By Value
  10. Immunoassays
    1. By Value
  11. PET
    1. By Value
  12. CT
    1. By Value
  13. Imaging Technologies
    1. By Value
  14. Proteomics
    1. By Value
  15. Omics Technologies
    1. By Value
  16. Other Cytogenetics
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Research
    1. By Value
  3. Risk Assessment
    1. By Value
  4. Prognostics
    1. By Value
  5. Diagnostics
    1. By Value
  6. Other Applications
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Genetic Biomarker
    1. By Value
  3. Protein Biomarker
    1. By Value
  4. Other Cancer Biomarkers
    1. By Value
2. By Cancer
  1. Introduction
    1. Cancer By Value
  2. Lung Cancer
    1. By Value
  3. Prostate Cancer
    1. By Value
  4. Melanoma
    1. By Value
  5. Thyroid CancerKidney Cancer
    1. By Value
  6. Bladder Cancer
    1. By Value
  7. Leukemia
    1. By Value
  8. Non-Hodgkin's lymphoma
    1. By Value
  9. Colorectal Cancer
    1. By Value
  10. Breast Cancer
    1. By Value
  11. Other Cancers
    1. By Value
3. By Profiling Technology
  1. Introduction
    1. Profiling Technology By Value
  2. Genomics
    1. By Value
  3. Other Omics Technology
    1. By Value
  4. Ultrasound
    1. By Value
  5. MRI
    1. By Value
  6. Mammography
    1. By Value
  7. Cytogenetics
    1. By Value
  8. Bioinformatics
    1. By Value
  9. In Situ Hybridization
    1. By Value
  10. Immunoassays
    1. By Value
  11. PET
    1. By Value
  12. CT
    1. By Value
  13. Imaging Technologies
    1. By Value
  14. Proteomics
    1. By Value
  15. Omics Technologies
    1. By Value
  16. Other Cytogenetics
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Research
    1. By Value
  3. Risk Assessment
    1. By Value
  4. Prognostics
    1. By Value
  5. Diagnostics
    1. By Value
  6. Other Applications
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Genetic Biomarker
  1. By Value
3. Protein Biomarker
  1. By Value
4. Other Cancer Biomarkers
  1. By Value
By Cancer
1. Introduction
  1. Cancer By Value
2. Lung Cancer
  1. By Value
3. Prostate Cancer
  1. By Value
4. Melanoma
  1. By Value
5. Thyroid CancerKidney Cancer
  1. By Value
6. Bladder Cancer
  1. By Value
7. Leukemia
  1. By Value
8. Non-Hodgkin's lymphoma
  1. By Value
9. Colorectal Cancer
  1. By Value
10. Breast Cancer
  1. By Value
11. Other Cancers
  1. By Value
By Profiling Technology
1. Introduction
  1. Profiling Technology By Value
2. Genomics
  1. By Value
3. Other Omics Technology
  1. By Value
4. Ultrasound
  1. By Value
5. MRI
  1. By Value
6. Mammography
  1. By Value
7. Cytogenetics
  1. By Value
8. Bioinformatics
  1. By Value
9. In Situ Hybridization
  1. By Value
10. Immunoassays
  1. By Value
11. PET
  1. By Value
12. CT
  1. By Value
13. Imaging Technologies
  1. By Value
14. Proteomics
  1. By Value
15. Omics Technologies
  1. By Value
16. Other Cytogenetics
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Research
  1. By Value
3. Risk Assessment
  1. By Value
4. Prognostics
  1. By Value
5. Diagnostics
  1. By Value
6. Other Applications
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Genetic Biomarker
    1. By Value
  3. Protein Biomarker
    1. By Value
  4. Other Cancer Biomarkers
    1. By Value
2. By Cancer
  1. Introduction
    1. Cancer By Value
  2. Lung Cancer
    1. By Value
  3. Prostate Cancer
    1. By Value
  4. Melanoma
    1. By Value
  5. Thyroid CancerKidney Cancer
    1. By Value
  6. Bladder Cancer
    1. By Value
  7. Leukemia
    1. By Value
  8. Non-Hodgkin's lymphoma
    1. By Value
  9. Colorectal Cancer
    1. By Value
  10. Breast Cancer
    1. By Value
  11. Other Cancers
    1. By Value
3. By Profiling Technology
  1. Introduction
    1. Profiling Technology By Value
  2. Genomics
    1. By Value
  3. Other Omics Technology
    1. By Value
  4. Ultrasound
    1. By Value
  5. MRI
    1. By Value
  6. Mammography
    1. By Value
  7. Cytogenetics
    1. By Value
  8. Bioinformatics
    1. By Value
  9. In Situ Hybridization
    1. By Value
  10. Immunoassays
    1. By Value
  11. PET
    1. By Value
  12. CT
    1. By Value
  13. Imaging Technologies
    1. By Value
  14. Proteomics
    1. By Value
  15. Omics Technologies
    1. By Value
  16. Other Cytogenetics
    1. By Value
4. By Application
  1. Introduction
    1. Application By Value
  2. Research
    1. By Value
  3. Risk Assessment
    1. By Value
  4. Prognostics
    1. By Value
  5. Diagnostics
    1. By Value
  6. Other Applications
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Cancer Biomarker Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Becton Dickinson (U.S.)
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Merck & Co. Inc. (U.S.),
Novartis AG (Switzerland)
PerkinElmer Inc. (U.S.)
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Thermo Fisher Scientific, Inc.
Bristol-Myers Squibb Company
Qiagen N.V.
Siemens AG
Exact Sciences Corporation
Bio-Rad Laboratories
Illumina
Agilent Technologies Inc.
Hologic, Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment